FDA warned International Laboratories Corp, a Thai drug manufacturer, over fabricated lab records and inadequate CGMP controls.
What happened
FDA inspected International Laboratories Corp's drug manufacturing facility in Samut Prakan, Thailand, from September 16 to 20, 2024. Investigators found fabricated laboratory records and investigations, deleted electronic raw data, and missing original testing and manufacturing records. FDA called the firm's October 11, 2024 response inadequate.
What FDA found
Laboratory records did not include complete, reliable original data; the firm fabricated several laboratory investigations and did not keep original raw-material and finished-product test data.
21 CFR 211.194(a)Laboratory computer systems lacked restricted access and controls, so analysts could change or delete data, and electronic raw data files were deleted or unavailable.
21 CFR 211.68(b)The quality control unit lacked adequate oversight and the firm could not provide records for finished-product release testing, stability testing, sample collection and preparation, data review procedures, or batch production and control records.
21 CFR 211.22(a)
What FDA wants
FDA tells the firm to correct the violations promptly and respond in writing within 15 working days with comprehensive data-integrity and quality-unit remediation plans; it recommends an independent qualified consultant. If corrective actions cannot be completed in that time, the firm must explain the delay and provide a schedule.
Who should pay attention
- companies that buy or distribute drugs made by this Thai manufacturer
- brands relying on its release or stability testing
- quality teams managing suppliers on Import Alert 66-40
This is a summary. Read the original letter on fda.gov.